Quantity Add to cart Inquiry
| Product Name | Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer, HEK293 |
| Cat. No. | MHCRP-0415 |
| Category | Proteins & Peptides |
| Product Description | Recombinant Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVVGAVGVGK peptide. |
| Size | 100/500 μg |
| Format | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Storage | Store at -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Shipping Temp | Shipped with dry ice. |
| Lead Time | Product delivery time depends on the supplier. |
| Species | Human |
| Expression Host | HEK293 |
| Accession No | AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAVGVGK |
| Tag | C-His-Avi |
| Tag Position | C-terminus |
| Molecular Type | Monomer |
| Molecular Weight (MV) | The protein has a predicted MW of 50.3 kDa. Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result. |
| Gene Synonyms | MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD |
| Purity | > 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC. |
| Amino Acid Range | Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M), and VVVGAVGVGK peptide |
| Activity | Immobilized biotinylated human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) monomer, His tag at 1 μg/mL (100 μL/well) on the streptavidin precoated plate (5 μg/mL). Dose response curve for anti-B2M antibody, mFc tag with the EC50 of 10.7 ng/mL determined by ELISA (QC Test). |
| Product Background | Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. |
| Allele | HLA-A*11:01 |
| Biotinylated | Yes |
Tel:
One-stop service